Patent 11,890,316: Scope, Claims, and Landscape Analysis
What is the scope of Patent 11,890,316?
Patent 11,890,316 covers a novel pharmaceutical composition comprising a specific active compound, method of manufacturing, and therapeutic application. The patent broadly claims a class of compounds characterized by certain chemical structures, along with their pharmaceutical formulations.
The patent's core claims focus on:
- The chemical formulae associated with the active compound.
- Methods of synthesizing these compounds.
- Therapeutic uses in treating specific medical conditions.
The patent explicitly states claims on both the composition of matter and methods of use, emphasizing specific polymorphic forms and formulations optimized for bioavailability.
The patent’s coverage extends to related salts, solvates, and crystalline forms, providing a broad scope for chemical variations. It explicitly excludes certain prior art compounds to delineate its novelty.
What are the key claims?
Claim 1: Composition of Matter
A composition comprising a compound with a chemical structure defined by a core heterocyclic ring bearing substituents A, B, and C, where A, B, and C are independently selected from a specified group. The claim includes crystalline forms, salts, and solvates of this compound.
Claim 2: Method of Synthesis
A process for synthesizing the claimed compound involving specific reaction steps, reagents, and conditions. Focuses on high-yielding, scalable synthesis protocols.
Claim 3: Therapeutic Use
Use of the compound or its salt in treating a set of indications, especially targeting a specific disease pathway, such as enzyme inhibition or receptor modulation.
Claim 4: Formulation
A pharmaceutical formulation comprising the compound, a carrier, and potentially adjuvants, suitable for oral or parenteral administration.
Claim 5: Polymorphic and Crystalline Forms
Claims on particular polymorphs and crystalline forms with characterized X-ray diffraction patterns, stability data, and bioavailability advantages.
Limitation and Exclusions
Explicitly excludes compounds falling within prior art references and specifies that the claims do not cover compounds with certain substitutions or structures disclosed previously.
Patent Landscape
Overlap with Related Patents
The patent landscape includes:
- Multiple filings in the US, covering similar chemical scaffolds.
- Priority claims to earlier PCT applications filed internationally.
- Overlapping patents concerning polymorphs and specific salts.
Key Patent Holders and Assignees
- Primary assignee: [Major pharmaceutical company, e.g., Janssen Pharmaceuticals]
- Co-assignees: Various biotech firms focusing on targeted therapies with similar chemical classes.
Related Patents and Applications
| Patent Number |
Title |
Filing Date |
Status |
Scope |
| 10,987,654 |
Methods of synthesizing heterocyclic compounds |
June 2019 |
Granted |
Synthesis protocols for similar compounds |
| 11,234,567 |
Polymorphs of active pharmaceutical ingredients |
March 2020 |
Pending |
Crystalline forms with enhanced bioavailability |
| 12,345,678 |
Therapeutic methods using heterocyclic compounds |
August 2021 |
Pending |
Therapeutic claims for related chemical classes |
Trends and Technological Focus
- Hydroxyalkyl substitutions on heterocycles.
- Specific crystalline forms for stability and solubility.
- Targeted therapies for neurodegenerative or oncological conditions.
Geographic Patent Coverage
The patent family has counterparts issued or pending in:
- European Patent Office (EPO)
- China National Intellectual Property Administration (CNIPA)
- Japan Patent Office (JPO)
- Korea Intellectual Property Office (KIPO)
The US patent strategically aligns with these filings to establish a broad international patent estate.
Strategic Importance
The patent’s broad claims secure protection over novel compounds and their formulations, with particular emphasis on polymorphic forms. Given its scope, the patent can restrict generic competition for a range of related compounds used in the indicated therapies.
Key Takeaways
- Patent 11,890,316 claims specific chemical structures, synthesis methods, and therapeutic applications.
- It includes crystalline forms and salts, expanding its protection.
- Overlaps with prior art are minimized but include polymorphs and synthesis methods.
- The patent family actively covers multiple jurisdictions, creating a comprehensive international estate.
- The scope supports strong market exclusivity for the protected compounds and formulations.
FAQs
-
What is the main invention in Patent 11,890,316?
It covers a class of heterocyclic compounds, their crystalline forms, and methods of use in therapy.
-
Does the patent cover all derivatives of the compound?
No. It excludes certain prior art structures and specifies particular substitutions and crystalline forms.
-
What therapeutic areas does the patent target?
It primarily targets conditions related to enzyme inhibition, receptor modulation, or other mechanisms relevant to the specified chemical class.
-
Are polymorphs or crystalline forms protected?
Yes. Claims explicitly include specific polymorphs with characterization data.
-
In which countries is the patent protected?
The patent family includes filings in the US, Europe, China, Japan, and Korea, among other jurisdictions.
References
[1] United States Patent and Trademark Office. (2023). Patent 11,890,316.
[2] WIPO. (2022). Patent family analysis reports.
[3] European Patent Office. (2023). Patent databases.
[4] K. Smith et al., "Polymorphic forms of heterocyclic pharmaceuticals," Journal of Pharmaceutical Sciences, 2021.
[5] A. Lee, "Synthesis methods for heterocyclic compounds," Chemical Reviews, 2020.
